Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies.
Isabel BergeriMairead G WhelanHarriet WareLorenzo SubissiAnthony NardoneHannah C LewisZihan LiXiaomeng MaMarta ValencianoBrianna ChengLubna Al AriqiArash RashidianJoseph OkeibunorTasnim AzimPushpa WijesingheLinh-Vi LeAisling M VaughanRichard PebodyAndrea VicariTingting YanMercedes Yanes-LaneChristian CaoDavid A CliftonMatthew Pellan ChengJesse PapenburgDavid BuckeridgeNiklas BobrovitzRahul Krishan AroraMaria D Van Kerkhovenull nullPublished in: PLoS medicine (2022)
In this study, we observed that global seroprevalence has risen considerably over time and with regional variation; however, over one-third of the global population are seronegative to the SARS-CoV-2 virus. Our estimates of infections based on seroprevalence far exceed reported Coronavirus Disease 2019 (COVID-19) cases. Quality and standardized seroprevalence studies are essential to inform COVID-19 response, particularly in resource-limited regions.